<DOC>
	<DOCNO>NCT00866307</DOCNO>
	<brief_summary>This pilot clinical trial study side effect pegaspargase give together combination chemotherapy treat patient newly diagnose high-risk acute lymphoblastic leukemia . Pegaspargase may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving one drug ( combination chemotherapy ) together pegaspargase may kill cancer cell .</brief_summary>
	<brief_title>Pegaspargase Combination Chemotherapy Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia ( Closed Accrual 4-22-2011 )</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To demonstrate biweekly intravenous ( IV ) pegaspargase begin Consolidation end completion delay intensification ( DI ) combination hemi-augmented BFM therapy ( hABFM ) feasible safe child high risk ( HR ) acute lymphoblastic leukemia ( ALL ) . OUTLINE : Patients stratify accord risk assignment ( high-risk [ HR ] -average [ day 29 minimal residual disease ( MRD ) &lt; 0.01 % ] vs HR-high [ MRD &gt; = 0.01 % , presence central nervous system [ CNS ] 3 leukemia , testicular disease , myeloid/mixed lineage leukemia [ MLL ] rearrangement , hypodiploidy , steroid therapy within past month ] ) . Patients assign 1 2 treatment group . * ( Note : *Amendment 2 [ 4-22-2011 ] require change regimen . See change , Maintenance therapy . ) INDUCTION THERAPY : All patient receive cytarabine intrathecally ( IT ) day 1 ; vincristine sulfate IV day 1 , 8 , 15 , 22 ; prednisone IV orally ( PO ) twice daily ( BID ) day 1-28 ; daunorubicin hydrochloride IV 15 minute day 1 , 8 , 15 , 22 ; methotrexate IT day 8 29* ; pegaspargase IV 1-2 hour day 4 . ( Note : *Patients CNS3 disease [ white blood cell [ ( WBC ) ] &gt; = 5/uL positive blast cytospin ] also receive methotrexate IT day 15 22 . ) CONSOLIDATION THERAPY ( begin day 36 induction therapy ) : GROUP A ( HR-AVERAGE ) : Patients receive cyclophosphamide IV 1 hour day 1 29 ; cytarabine IV 15 minute subcutaneously ( SC ) day 1-4 , 8-11 , 29-32 , 36-39 ; mercaptopurine PO daily ( QD ) day 1-14 29-42 ; vincristine sulfate IV day 15 , 22 , 43 , 50 ; methotrexate IT day 1 , 8 , 15* , 22* ; pegaspargase IV 1-2 hour day 15 43 . GROUP B ( HR-HIGH ) : Patients receive cyclophosphamide , cytarabine , mercaptopurine , vincristine sulfate , methotrexate Group A . Beginning day 1 , patient also receive pegaspargase IV 1-2 hour every 2 week . Patients CNS3 disease undergo cranial radiotherapy QD 10 day patient testicular disease undergo testicular radiotherapy QD 12 day , begin day 1 consolidation . ( Note : *Patients CNS3 disease [ WBC &gt; = 5/uL positive blast cytospin ] receive methotrexate IT day 15 22 . ) Interim maintenance ( IM ) therapy ( begin day 57 consolidation ) : GROUP A : Patients receive vincristine sulfate IV day 1 , 11 , 21 , 31 , 41 ; methotrexate IV 10-15 minute day 1 , 11 , 21 , 31 , 41 ; methotrexate IT day 1 31 ; pegaspargase IV 1-2 hour day 2 22 . GROUP B : Patients receive vincristine sulfate methotrexate Group A . Beginning day 1 , patient also receive pegaspargase IV 1-2 hour every 2 week . DI therapy ( begin day 57 IM ) : GROUP A : Patients receive vincristine sulfate IV day 1 , 8 , 15 , 43 , 50 ; dexamethasone IV PO BID day 1-7 15-21 ; doxorubicin hydrochloride IV 15 minute day 1 , 8 , 15 ; cyclophosphamide IV 1 hour day 29 ; cytarabine IV 15 minute SC day 29-32 36-39 ; thioguanine PO day 29-42 ; methotrexate IT day 1 , 29 , 36 ; pegaspargase IV 1-2 hour day 4 43 . GROUP B : Patients receive vincristine sulfate , dexamethasone , doxorubicin hydrochloride , cyclophosphamide , cytarabine , thioguanine , methotrexate Group A . Beginning day 1 , patient also receive pegaspargase IV 1-2 hour every 2 week . MAINTENANCE THERAPY ( MT ; begin day 57 DI ) : All patient receive vincristine sulfate IV day 1 , 29 , 57 ; prednisone PO BID day 1-5 , 29-33 , 57-61 ; mercaptopurine PO day 1-84 ; methotrexate IT day 1 ; methotrexate PO BID day 8 , 15 , 22 , 29* , 36 , 43 , 50 , 57 , 64 , 71 , 78 . In group , MT repeat every 12 week total duration therapy 2 year start IM female patient 3 year start IM male patient . Patients Group B undergo radiotherapy brain consolidation therapy undergo prophylactic cranial radiotherapy ( CR ) daily 8 day . ( [ Note : *Patients Group A also receive methotrexate IT day 29 course 1-4 [ oral methotrexate ] ) . REVISED MT ( RMT ) : The regimen standard MT , 2 dos IT methotrexate omit ( day 29 course 3 4 ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients must eligible enrolled AALL03B1 successor classification study Patients must newly diagnose highrisk Bprecursor acute lymphoblastic leukemia ( ALL ) WBC criterion Age 1.009.99 year : WBC &gt; = 50,000/uL Age 10.00 30.99 year : Any WBC Prior steroid therapy : Any WBC Patients testicular leukemia : Any WBC Patients shall prior cytotoxic chemotherapy exception steroid intrathecal cytarabine Intrathecal chemotherapy cytarabine allow prior registration patient convenience ; usually do time diagnostic bone marrow venous line placement avoid second lumbar puncture ; CNS status must determine base sample obtain prior administration systemic intrathecal chemotherapy , except steroid pretreatment ; systemic chemotherapy must begin within 72 hour intrathecal therapy Patients receive prior steroid therapy eligible study ; dose duration previous steroid therapy carefully document All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Pregnant female patient ineligible ; pregnancy test negative result must obtain postmenarchal female ; male female reproductive potential may participate unless agree use effective contraceptive method ; lactate female must agree breastfeed child study Patients Down syndrome ( DS ) ineligible since excessive toxicity death note enrolled AALL0232 receive prednisone/Capizzi methotrexate ( PC ) arm treatment , backbone regimen current study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>